MedTrace Logo

LRAs United as a Novel Anti-HIV Strategy.

NCT03525730 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2021-04-29

No results posted yet for this study

Summary

A translational proof of concept study in humans on the primary research question whether novel anti-human immunodeficiency virus (HIV) latency strategies, including a BAF inhibitor and a histone deacetylase inhibitor, result in HIV reservoir reduction in HIV patients on antiretroviral therapy.

Conditions

Interventions

DRUG

Valproic Acid

Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.

DRUG

Pyrimethamine

Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.

Sponsors & Collaborators

Principal Investigators

  • Casper Rokx, MD PhD · Erasmus Medical Center

  • Tokameh Mahmoudi, PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2019-07-25
Completion
2020-10-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03525730 on ClinicalTrials.gov